Search

News Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene

PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt −⁠ wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.

Source: Colorectal Cancer 14. 10. 2023

News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab

Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.

Source: Quality Life Even with Hemophilia 28. 7. 2020

News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL –⁠ results from the open part of the ECHELON-3 study

The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Source: Hematologic Malignancies 10. 8. 2022

News International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders

At the end of December 2020, international guidelines for COVID-19 vaccination in people with bleeding disorders were published on the World Federation of Hemophilia (WFH) website. We present a basic summary of 13 points of this consensus. The original English version is available via the web link cited at the end of the article.

Source: Hemophilia 8. 2. 2021

News Early Detection of Erectile Dysfunction in Men with Type 2 Diabetes

A retrospective study published last year identified predictors of erectile dysfunction in men with type 2 diabetes. The authors recommend screening patients with elevated uric acid levels, diabetes duration ≥ 49 months, and diabetic retinopathy.

Source: Diabetes 18. 7. 2022

News Study PLATON: romiplostim in patients with ITP in real clinical practice

Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.

Source: Immune Thrombocytopenia 8. 6. 2020

News Does gliflozin treatment for heart failure have greater benefits in diabetics?

Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of empagliflozin administration in individuals with heart failure with reduced ejection fraction (HFrEF) and compared the results in patients with and without diabetes.

Source: Heart Failure 3. 3. 2022

News Retention –⁠ An Overlooked Parameter of Incontinence Products

In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?

Source: Incontinence 9. 4. 2021

News Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention

Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent thrombosis, and cerebrovascular stroke (CVS). The meta-analysis presented below attempted to clarify which antithrombotic regimen is most suitable in terms of safety and efficacy for these patients.

Source: Anticoagulant Treatment 13. 3. 2020

News Extended Thromboprophylaxis with Enoxaparin After Bariatric Surgery

A recent retrospective study involving 312 patients after bariatric surgery indicated that extended thromboprophylaxis might be an appropriate approach for preventing postoperative venous thromboembolism in these patients. In this study, the authors administered enoxaparin at a dose of 40 mg subcutaneously twice daily for 10-14 days in the majority of operated patients without an increased risk of bleeding.

Source: Thromboprophylaxis 29. 4. 2021

News Thinking About Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis (IPF) is one of the most prognostically severe and difficult-to-treat lung diseases. It affects about 5 million people worldwide, with an estimated incidence in the Czech Republic of 1/100,000 inhabitants. Although it is a relatively rare disease, due to its high mortality rate (the median survival of untreated patients is 2−3 years), it is essential to have a basic awareness of the possible symptoms of IPF. Expert sources even state that, according to statistics, only pancreatic cancer leads to a faster death compared to untreated pulmonary fibrosis.

Source: Pulmonary Fibrosis 16. 4. 2020

News Development of Albuminuria During Treatment with ACE Inhibitors and Sartans

Individual molecules from the class of renin-angiotensin system inhibitors display various distinct properties at the molecular level, and their renoprotective potential may differ. A study by Korean authors observed the development of renal parameters in individuals with albuminuria during the first 3 months after the initiation of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), also known as sartans.

Source: Sartans in the Treatment of Hypertension 25. 5. 2020

News Regular Walking as an Intervention to Support the Quality of Life of Diabetics

Diabetes mellitus (DM), as a chronic and in many cases disabling disease, limits patients in various aspects of their lives. Therefore, it is important to consider the quality of life of diabetics as part of treatment and to seek ways to appropriately support it and enable patients to be as actively involved in everyday life as possible. The American journal Diabetes Care published the results of a study evaluating the impact of regular walking on the quality of life in DM.

Source: Diabetes 25. 2. 2020

News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling

A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.

Source: Chronic Heart Failure and Lipidology 1. 6. 2020

News Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks

Berotralstat is an oral medication administered once daily, developed to prevent hereditary angioedema (HAE) attacks. It is a kallikrein protease inhibitor, which plays a key role in the pathogenesis of this disease. A phase III clinical trial, with results recently published in the Journal of Allergy and Clinical Immunology, evaluated the efficacy and safety of two dosing regimens of berotralstat compared to placebo in patients with HAE.

Source: Hereditary Angioedema 25. 2. 2022